BioNTech SE reports recurring developments as a Germany-based biotechnology company whose ADSs trade on Nasdaq. Company news centers on oncology pipeline progress across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies, including lung cancer programs such as pumitamig and gotistobart, as well as COVID-19 vaccine activity tied to its commercial vaccine franchise.
Updates also cover quarterly and annual financial results, research and development spending, corporate presentations, capital allocation actions such as ADS repurchase authorizations, and shareholder meeting or governance matters. BioNTech news frequently links clinical data, partnership activity and operating priorities to its broader objective of building a multi-product biotechnology business.
BioNTech (NASDAQ:BNTX) and Pfizer have received a positive CHMP opinion for their LP.8.1-adapted COVID-19 vaccine in the European Union. The updated vaccine demonstrates improved immune response against dominant variants including XFG and NB.1.8.1 compared to 2024-2025 formulations.
Upon European Commission authorization, the vaccine will be available for individuals 6 months and older. The companies have already initiated manufacturing to ensure supply readiness for the upcoming fall/winter season, with doses ready to ship immediately following EC approval.
The recommendation is supported by comprehensive clinical, non-clinical, and real-world data, with over a billion doses administered globally demonstrating favorable safety and efficacy profiles.
BioNTech (NASDAQ: BNTX) has scheduled its second quarter 2025 financial results announcement and corporate update for August 4, 2025. The company will host a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) on the same day.
Investors and analysts can access the conference call via telephone by registering through a provided link, which will supply dial-in numbers and a PIN. The presentation slides and webcast will be accessible through the company's website, with a replay available for 30 days after the event.
BioNTech (NASDAQ: BNTX) announced that Chief Strategy Officer Ryan Richardson will step down from the Management Board effective September 30, 2025. Richardson, who joined in 2018 and served as CSO since January 2020, played a crucial role in the company's development, including raising over $1 billion in capital through Series B financing, IPO, and follow-on offerings.
During his tenure, Richardson led Global Strategy and Corporate Development functions, overseeing more than a dozen collaborations and acquisitions. He also managed Capital Markets and Investor Relations, expanding analyst coverage and strengthening BioNTech's global shareholder base. His responsibilities will be transitioned to other Management Board members to ensure a smooth handover.
BioNTech (NASDAQ: BNTX) has appointed Ramón Zapata-Gomez as its new Chief Financial Officer, effective July 1, 2025. Zapata will succeed Jens Holstein, who will retire as planned on June 30, 2025. Zapata joins from Novartis AG, where he served as CFO of their global biomedical research organization since 2022.
With over 25 years of experience in pharmaceutical and consumer goods industries, Zapata brings extensive expertise in finance, M&A, and digital transformations. His appointment aligns with BioNTech's strategy to become a multi-product oncology company. In his new role, Zapata will focus on optimizing financial infrastructure, performance in key markets, and driving cost-effective value generation as the company prepares for oncology product launches.
BioNTech (NASDAQ: BNTX) will showcase data from its oncology pipeline at the AACR Annual Meeting in Chicago (April 25-30, 2025). The presentations will feature:
1. BNT327: A next-generation bispecific antibody showing superior anti-tumor activity in preclinical studies when combined with antibody-drug conjugates (ADCs)
2. BNT116: Phase 1 clinical trial data in combination with cemiplimab for non-small cell lung cancer (NSCLC), demonstrating anti-tumor activity and manageable safety profile
3. BNT314/GEN1059: Preclinical data showing enhanced anti-tumor activity when combined with PD-1 inhibition
The company's oncology portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, with over 20 active Phase 2 and 3 trials. Multiple data readouts are expected in 2025 and 2026.
BioNTech SE (Nasdaq: BNTX) has announced it will release its first quarter 2025 financial results on Monday, May 5, 2025. The company will host a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) to discuss the financial results and provide a corporate update.
Investors, financial analysts, and the public can access the conference call via telephone by registering through a provided link, which will supply dial-in numbers and a PIN. Registration is recommended at least one day in advance. The webcast and slide presentation will be accessible through the company's Investor Relations section, with a replay available for 30 days after the call.